Whether the high incidence of venous thromboembolism (VTE) in the elderly can be attributed to cancer is not well studied. We assessed the impact of cancer on risk of VTE in young, middle-aged and elderly. 26,094 subjects without a history of cancer or VTE were recruited from the Tromsø study. Incident cancer (n = 2,290) and VTE (n = 531) were recorded from baseline (1994–1995) through December 31st, 2009. Cox regression with cancer as time-varying exposure was used to calculate hazard ratios with 95 % confidence intervals (CI). Overt cancer was associated with a fivefold (95 %CI 4.3, 6.7) increased risk of VTE, with an age-dependent gradient from 26-fold (95 %CI 12.1, 56.5) increased in the young, ninefold (95 % CI 6.6, 12.7) increased in the middle-aged, and threefold (95 % CI 2.5, 4.5) increased risk in the elderly. The population attributable risks were 14, 27 and 18 %, respectively. Conclusion: The relative risk of VTE by cancer were higher in young compared to elderly subjects, but the proportion of VTEs in the population due to cancer did not differ much across age groups. Our findings indicate that the increased risk of VTE by advancing age cannot be attributed to higher incidence of cancer in the elderly.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4. doi:10.1111/j.1538-7836.2007.02374.x.
Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–9. doi:10.1111/j.1538-7836.2007.02450.x.
Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102(Suppl 1):S2–9. doi:10.1038/sj.bjc.6605599.
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22. doi:10.1001/jama.293.6.715.
Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19–25. doi:10.1016/j.amjmed.2004.01.018.
Braekkan SK, Borch KH, Mathiesen EB, Njolstad I, Wilsgaard T, Hansen JB. Body height and risk of venous thromboembolism: the Tromso study. Am J Epidemiol. 2010;171(10):1109–15. doi:10.1093/aje/kwq066.
Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P. Cancer and venous thromboembolism. Semin Thromb Hemost. 2006;32(7):694–9. doi:10.1055/s-2006-951297.
Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164(15):1653–61. doi:10.1001/archinte.164.15.1653.
Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–8. doi:10.1182/blood-2002-01-0108.
Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78(5):285–91.
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50. doi:10.1056/NEJM200012213432504.
Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–64. doi:10.1001/.458.
Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, Hansen JB. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. J Thromb Haemost. 2008;6(11):1851–7. doi:10.1111/j.1538-7836.2008.03102.x.
Norway S. Statistical yearbook of Norway 2009. 2009.
Rosendaal FR, Vanhv A, Doggen CJ. Venous thrombosis in the elderly. J Thromb Haemost. 2007;5(Suppl 1):310–7. doi:10.1111/j.1538-7836.2007.02489.x.
Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer. 2010;103(7):947–53. doi:10.1038/sj.bjc.6605883.
Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer—a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404–13. doi:10.1016/j.ejca.2012.10.021.
Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31. doi:10.1016/j.ejca.2008.10.037.
Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromso Study, Tromso, Norway. J Thromb Haemost. 2010;8(1):157–62. doi:10.1111/j.1538-7836.2009.03498.x.
Campigotto F, Neuberg D, Zwicker JI. Accounting for death as a competing risk in cancer-associated thrombosis studies. Thromb Res. 2012;129(Suppl 1):S85–7. doi:10.1016/S0049-3848(12)70023-3.
Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–15.
Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjonneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol. 2010;63(2):223–8. doi:10.1016/j.jclinepi.2009.03.018.
Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275. doi:10.1371/journal.pmed.1001275.
Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167–73.
Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010;8(10):2105–12. doi:10.1111/j.1538-7836.2010.03986.x.
Weingarz L, Schwonberg J, Schindewolf M, et al. Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry. Br J Haematol. 2013;163(5):655–65. doi:10.1111/bjh.12575.
The authors received grants from the Northern Norway Regional Health Authority (SK Brækkan and JB Hansen) and the Tom Wilhelmsen Foundation (K Blix). KB, SKB and JBH were involved in acquisition of the data, concept and design of the study, data analysis, interpretation of results and drafting the manuscript. SleC was involved in data analysis, interpretation and critical revision of the manuscript. FES and SCC contributed to interpretation of the results and critical revision of the manuscript. All authors approved the final version of the manuscript.
Conflict of interests
The authors declare that they have no conflict of interest.
About this article
Cite this article
Blix, K., Brækkan, S.K., le Cessie, S. et al. The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromsø study. Eur J Epidemiol 29, 277–284 (2014). https://doi.org/10.1007/s10654-014-9902-7
- Venous thromboembolism
- Age groups
- Cohort study
- Attributable risk